Scholar Rock (NASDAQ:SRRK) Earns Buy Rating from HC Wainwright

Scholar Rock (NASDAQ:SRRK)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $65.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 17.48% from the company’s previous close.

Several other brokerages also recently issued reports on SRRK. BMO Capital Markets reiterated an “outperform” rating and issued a $76.00 target price on shares of Scholar Rock in a research note on Friday, August 7th. Wedbush restated an “outperform” rating and issued a $64.00 price objective on shares of Scholar Rock in a report on Friday, August 21st. Citigroup upped their price objective on Scholar Rock from $58.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a report on Friday, July 17th. Four analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $58.77.

Scholar Rock Price Performance

Shares of NASDAQ:SRRK opened at $55.33 on Tuesday. The company has a current ratio of 7.02, a quick ratio of 7.02 and a debt-to-equity ratio of 0.77. The stock has a fifty day simple moving average of $53.45 and a two-hundred day simple moving average of $49.30. Scholar Rock has a 12-month low of $27.07 and a 12-month high of $61.76. The stock has a market capitalization of $6.74 billion, a price-to-earnings ratio of -16.04 and a beta of 0.67.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Thursday, August 6th. The company reported ($0.84) EPS for the quarter, hitting analysts’ consensus estimates of ($0.84). During the same period in the previous year, the firm earned ($0.98) earnings per share. On average, research analysts anticipate that Scholar Rock will post -3.23 earnings per share for the current fiscal year.

Insider Activity at Scholar Rock

In other Scholar Rock news, Director Jeffrey Flier sold 3,053 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total value of $164,495.64. Following the transaction, the director owned 27,856 shares of the company’s stock, valued at approximately $1,500,881.28. This represents a 9.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael Gilman sold 2,544 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total transaction of $137,045.28. Following the sale, the director directly owned 59,511 shares of the company’s stock, valued at $3,205,857.57. The trade was a 4.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 17,149 shares of company stock valued at $923,108 in the last 90 days. 10.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Scholar Rock

A number of hedge funds have recently modified their holdings of the company. IFP Advisors Inc raised its position in shares of Scholar Rock by 294.1% during the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after purchasing an additional 450 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in Scholar Rock during the 4th quarter valued at approximately $30,000. Summit Securities Group LLC purchased a new position in Scholar Rock in the 4th quarter worth approximately $31,000. Allworth Financial LP bought a new position in Scholar Rock in the 2nd quarter worth approximately $35,000. Finally, EverSource Wealth Advisors LLC grew its holdings in Scholar Rock by 151.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after buying an additional 525 shares in the last quarter. 91.08% of the stock is currently owned by institutional investors.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).